Magnesium–ibogaine therapy in veterans with traumatic brain injuries
Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression and anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complicatio...
Gespeichert in:
| Veröffentlicht in: | Nature medicine 2024-02, Vol.30 (2), p.373-381 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 381 |
|---|---|
| container_issue | 2 |
| container_start_page | 373 |
| container_title | Nature medicine |
| container_volume | 30 |
| creator | Cherian, Kirsten N. Keynan, Jackob N. Anker, Lauren Faerman, Afik Brown, Randi E. Shamma, Ahmed Keynan, Or Coetzee, John P. Batail, Jean-Marie Phillips, Angela Bassano, Nicholas J. Sahlem, Gregory L. Inzunza, Jose Millar, Trevor Dickinson, Jonathan Rolle, C. E. Keller, Jennifer Adamson, Maheen Kratter, Ian H. Williams, Nolan R. |
| description | Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression and anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complications, leading some to seek underexplored treatment alternatives such as the oneirogen ibogaine, a plant-derived compound known to interact with multiple neurotransmitter systems that has been studied primarily as a treatment for substance use disorders. Ibogaine has been associated with instances of fatal cardiac arrhythmia, but coadministration of magnesium may mitigate this concern. In the present study, we report a prospective observational study of the Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS protocol (MISTIC), provided together with complementary treatment modalities, in 30 male SOVs with predominantly mild TBI. We assessed changes in the World Health Organization Disability Assessment Schedule from baseline to immediately (primary outcome) and 1 month (secondary outcome) after treatment. Additional secondary outcomes included changes in PTSD (Clinician-Administered PTSD Scale for DSM-5), depression (Montgomery–Åsberg Depression Rating Scale) and anxiety (Hamilton Anxiety Rating Scale). MISTIC resulted in significant improvements in functioning both immediately (
P
corrected
|
| doi_str_mv | 10.1038/s41591-023-02705-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10878970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2918195637</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-f5535f5c48d93cd2c7714724d7a8a0268a344c7e72087d82531e1ad62b3a35503</originalsourceid><addsrcrecordid>eNp9kUtOwzAQhi0EoqVwARYoEhs2AT_i2FkhVFFAKmIDEjvLdZzUVeMUO2nVHXfghpwEl5byWLAYzUjzze8Z_wAcI3iOIOEXPkE0QzHEJASDNF7sgC6iSRojBp93Qw0Zj3lG0w448H4CISSQZvugQzjimPGkCwb3srTam7Z6f30zo7qUxuqoGWsnZ8vI2Gium1BbHy1MM44aJ9tKNkZFIxfIAExaZ7Q_BHuFnHp9tMk98DS4fuzfxsOHm7v-1TBWFPImLigltKAq4XlGVI4VYyhhOMmZ5BLilEuSJIpphiFnOceUII1knuIRkYRSSHrgcq07a0eVzpW2YaOpmDlTSbcUtTTid8easSjruUBBkGdspXC2UXD1S6t9IyrjlZ5OpdV16wXOEEfhywgL6OkfdFK3zob7AoU5wyglNFB4TSlXe-90sd0GQbHySax9EsEn8emTWIShk593bEe-jAkAWQM-tGyp3ffb_8h-AEP8n8I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2928721635</pqid></control><display><type>article</type><title>Magnesium–ibogaine therapy in veterans with traumatic brain injuries</title><source>MEDLINE</source><source>Nature</source><source>SpringerLink Journals - AutoHoldings</source><creator>Cherian, Kirsten N. ; Keynan, Jackob N. ; Anker, Lauren ; Faerman, Afik ; Brown, Randi E. ; Shamma, Ahmed ; Keynan, Or ; Coetzee, John P. ; Batail, Jean-Marie ; Phillips, Angela ; Bassano, Nicholas J. ; Sahlem, Gregory L. ; Inzunza, Jose ; Millar, Trevor ; Dickinson, Jonathan ; Rolle, C. E. ; Keller, Jennifer ; Adamson, Maheen ; Kratter, Ian H. ; Williams, Nolan R.</creator><creatorcontrib>Cherian, Kirsten N. ; Keynan, Jackob N. ; Anker, Lauren ; Faerman, Afik ; Brown, Randi E. ; Shamma, Ahmed ; Keynan, Or ; Coetzee, John P. ; Batail, Jean-Marie ; Phillips, Angela ; Bassano, Nicholas J. ; Sahlem, Gregory L. ; Inzunza, Jose ; Millar, Trevor ; Dickinson, Jonathan ; Rolle, C. E. ; Keller, Jennifer ; Adamson, Maheen ; Kratter, Ian H. ; Williams, Nolan R.</creatorcontrib><description>Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression and anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complications, leading some to seek underexplored treatment alternatives such as the oneirogen ibogaine, a plant-derived compound known to interact with multiple neurotransmitter systems that has been studied primarily as a treatment for substance use disorders. Ibogaine has been associated with instances of fatal cardiac arrhythmia, but coadministration of magnesium may mitigate this concern. In the present study, we report a prospective observational study of the Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS protocol (MISTIC), provided together with complementary treatment modalities, in 30 male SOVs with predominantly mild TBI. We assessed changes in the World Health Organization Disability Assessment Schedule from baseline to immediately (primary outcome) and 1 month (secondary outcome) after treatment. Additional secondary outcomes included changes in PTSD (Clinician-Administered PTSD Scale for DSM-5), depression (Montgomery–Åsberg Depression Rating Scale) and anxiety (Hamilton Anxiety Rating Scale). MISTIC resulted in significant improvements in functioning both immediately (
P
corrected
< 0.001, Cohen’s
d
= 0.74) and 1 month (
P
corrected
< 0.001,
d
= 2.20) after treatment and in PTSD (
P
corrected
< 0.001,
d
= 2.54), depression (
P
corrected
< 0.001,
d
= 2.80) and anxiety (
P
corrected
< 0.001,
d
= 2.13) at 1 month after treatment. There were no unexpected or serious adverse events. Controlled clinical trials to assess safety and efficacy are needed to validate these initial open-label findings. ClinicalTrials.gov registration:
NCT04313712
.
Military veterans with traumatic brain injuries who received treatment with the psychoactive compound ibogaine and magnesium experienced improvements in disability, psychiatric symptoms and cognition.</description><identifier>ISSN: 1078-8956</identifier><identifier>EISSN: 1546-170X</identifier><identifier>DOI: 10.1038/s41591-023-02705-w</identifier><identifier>PMID: 38182784</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>631/477 ; 692/308/409 ; Anxiety ; Arrhythmia ; Biomedical and Life Sciences ; Biomedicine ; Brain ; Brain Injuries, Traumatic - drug therapy ; Cancer Research ; Clinical trials ; Cognition ; Complications ; Head injuries ; Humans ; Ibogaine ; Infectious Diseases ; Injuries ; Magnesium ; Magnesium - therapeutic use ; Mental depression ; Mental disorders ; Metabolic Diseases ; Military personnel ; Military psychology ; Molecular Medicine ; Neurosciences ; Observational studies ; Plants ; Post traumatic stress disorder ; Psychological stress ; Signs and symptoms ; Substance use ; Traumatic brain injury ; Treatment Outcome ; Veterans - psychology</subject><ispartof>Nature medicine, 2024-02, Vol.30 (2), p.373-381</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-f5535f5c48d93cd2c7714724d7a8a0268a344c7e72087d82531e1ad62b3a35503</citedby><cites>FETCH-LOGICAL-c508t-f5535f5c48d93cd2c7714724d7a8a0268a344c7e72087d82531e1ad62b3a35503</cites><orcidid>0000-0001-9203-0730 ; 0000-0001-9122-4525 ; 0000-0001-8376-3406 ; 0000-0002-6153-217X ; 0000-0003-4368-3203</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41591-023-02705-w$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41591-023-02705-w$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38182784$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cherian, Kirsten N.</creatorcontrib><creatorcontrib>Keynan, Jackob N.</creatorcontrib><creatorcontrib>Anker, Lauren</creatorcontrib><creatorcontrib>Faerman, Afik</creatorcontrib><creatorcontrib>Brown, Randi E.</creatorcontrib><creatorcontrib>Shamma, Ahmed</creatorcontrib><creatorcontrib>Keynan, Or</creatorcontrib><creatorcontrib>Coetzee, John P.</creatorcontrib><creatorcontrib>Batail, Jean-Marie</creatorcontrib><creatorcontrib>Phillips, Angela</creatorcontrib><creatorcontrib>Bassano, Nicholas J.</creatorcontrib><creatorcontrib>Sahlem, Gregory L.</creatorcontrib><creatorcontrib>Inzunza, Jose</creatorcontrib><creatorcontrib>Millar, Trevor</creatorcontrib><creatorcontrib>Dickinson, Jonathan</creatorcontrib><creatorcontrib>Rolle, C. E.</creatorcontrib><creatorcontrib>Keller, Jennifer</creatorcontrib><creatorcontrib>Adamson, Maheen</creatorcontrib><creatorcontrib>Kratter, Ian H.</creatorcontrib><creatorcontrib>Williams, Nolan R.</creatorcontrib><title>Magnesium–ibogaine therapy in veterans with traumatic brain injuries</title><title>Nature medicine</title><addtitle>Nat Med</addtitle><addtitle>Nat Med</addtitle><description>Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression and anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complications, leading some to seek underexplored treatment alternatives such as the oneirogen ibogaine, a plant-derived compound known to interact with multiple neurotransmitter systems that has been studied primarily as a treatment for substance use disorders. Ibogaine has been associated with instances of fatal cardiac arrhythmia, but coadministration of magnesium may mitigate this concern. In the present study, we report a prospective observational study of the Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS protocol (MISTIC), provided together with complementary treatment modalities, in 30 male SOVs with predominantly mild TBI. We assessed changes in the World Health Organization Disability Assessment Schedule from baseline to immediately (primary outcome) and 1 month (secondary outcome) after treatment. Additional secondary outcomes included changes in PTSD (Clinician-Administered PTSD Scale for DSM-5), depression (Montgomery–Åsberg Depression Rating Scale) and anxiety (Hamilton Anxiety Rating Scale). MISTIC resulted in significant improvements in functioning both immediately (
P
corrected
< 0.001, Cohen’s
d
= 0.74) and 1 month (
P
corrected
< 0.001,
d
= 2.20) after treatment and in PTSD (
P
corrected
< 0.001,
d
= 2.54), depression (
P
corrected
< 0.001,
d
= 2.80) and anxiety (
P
corrected
< 0.001,
d
= 2.13) at 1 month after treatment. There were no unexpected or serious adverse events. Controlled clinical trials to assess safety and efficacy are needed to validate these initial open-label findings. ClinicalTrials.gov registration:
NCT04313712
.
Military veterans with traumatic brain injuries who received treatment with the psychoactive compound ibogaine and magnesium experienced improvements in disability, psychiatric symptoms and cognition.</description><subject>631/477</subject><subject>692/308/409</subject><subject>Anxiety</subject><subject>Arrhythmia</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain</subject><subject>Brain Injuries, Traumatic - drug therapy</subject><subject>Cancer Research</subject><subject>Clinical trials</subject><subject>Cognition</subject><subject>Complications</subject><subject>Head injuries</subject><subject>Humans</subject><subject>Ibogaine</subject><subject>Infectious Diseases</subject><subject>Injuries</subject><subject>Magnesium</subject><subject>Magnesium - therapeutic use</subject><subject>Mental depression</subject><subject>Mental disorders</subject><subject>Metabolic Diseases</subject><subject>Military personnel</subject><subject>Military psychology</subject><subject>Molecular Medicine</subject><subject>Neurosciences</subject><subject>Observational studies</subject><subject>Plants</subject><subject>Post traumatic stress disorder</subject><subject>Psychological stress</subject><subject>Signs and symptoms</subject><subject>Substance use</subject><subject>Traumatic brain injury</subject><subject>Treatment Outcome</subject><subject>Veterans - psychology</subject><issn>1078-8956</issn><issn>1546-170X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUtOwzAQhi0EoqVwARYoEhs2AT_i2FkhVFFAKmIDEjvLdZzUVeMUO2nVHXfghpwEl5byWLAYzUjzze8Z_wAcI3iOIOEXPkE0QzHEJASDNF7sgC6iSRojBp93Qw0Zj3lG0w448H4CISSQZvugQzjimPGkCwb3srTam7Z6f30zo7qUxuqoGWsnZ8vI2Gium1BbHy1MM44aJ9tKNkZFIxfIAExaZ7Q_BHuFnHp9tMk98DS4fuzfxsOHm7v-1TBWFPImLigltKAq4XlGVI4VYyhhOMmZ5BLilEuSJIpphiFnOceUII1knuIRkYRSSHrgcq07a0eVzpW2YaOpmDlTSbcUtTTid8easSjruUBBkGdspXC2UXD1S6t9IyrjlZ5OpdV16wXOEEfhywgL6OkfdFK3zob7AoU5wyglNFB4TSlXe-90sd0GQbHySax9EsEn8emTWIShk593bEe-jAkAWQM-tGyp3ffb_8h-AEP8n8I</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Cherian, Kirsten N.</creator><creator>Keynan, Jackob N.</creator><creator>Anker, Lauren</creator><creator>Faerman, Afik</creator><creator>Brown, Randi E.</creator><creator>Shamma, Ahmed</creator><creator>Keynan, Or</creator><creator>Coetzee, John P.</creator><creator>Batail, Jean-Marie</creator><creator>Phillips, Angela</creator><creator>Bassano, Nicholas J.</creator><creator>Sahlem, Gregory L.</creator><creator>Inzunza, Jose</creator><creator>Millar, Trevor</creator><creator>Dickinson, Jonathan</creator><creator>Rolle, C. E.</creator><creator>Keller, Jennifer</creator><creator>Adamson, Maheen</creator><creator>Kratter, Ian H.</creator><creator>Williams, Nolan R.</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9203-0730</orcidid><orcidid>https://orcid.org/0000-0001-9122-4525</orcidid><orcidid>https://orcid.org/0000-0001-8376-3406</orcidid><orcidid>https://orcid.org/0000-0002-6153-217X</orcidid><orcidid>https://orcid.org/0000-0003-4368-3203</orcidid></search><sort><creationdate>20240201</creationdate><title>Magnesium–ibogaine therapy in veterans with traumatic brain injuries</title><author>Cherian, Kirsten N. ; Keynan, Jackob N. ; Anker, Lauren ; Faerman, Afik ; Brown, Randi E. ; Shamma, Ahmed ; Keynan, Or ; Coetzee, John P. ; Batail, Jean-Marie ; Phillips, Angela ; Bassano, Nicholas J. ; Sahlem, Gregory L. ; Inzunza, Jose ; Millar, Trevor ; Dickinson, Jonathan ; Rolle, C. E. ; Keller, Jennifer ; Adamson, Maheen ; Kratter, Ian H. ; Williams, Nolan R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-f5535f5c48d93cd2c7714724d7a8a0268a344c7e72087d82531e1ad62b3a35503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>631/477</topic><topic>692/308/409</topic><topic>Anxiety</topic><topic>Arrhythmia</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain</topic><topic>Brain Injuries, Traumatic - drug therapy</topic><topic>Cancer Research</topic><topic>Clinical trials</topic><topic>Cognition</topic><topic>Complications</topic><topic>Head injuries</topic><topic>Humans</topic><topic>Ibogaine</topic><topic>Infectious Diseases</topic><topic>Injuries</topic><topic>Magnesium</topic><topic>Magnesium - therapeutic use</topic><topic>Mental depression</topic><topic>Mental disorders</topic><topic>Metabolic Diseases</topic><topic>Military personnel</topic><topic>Military psychology</topic><topic>Molecular Medicine</topic><topic>Neurosciences</topic><topic>Observational studies</topic><topic>Plants</topic><topic>Post traumatic stress disorder</topic><topic>Psychological stress</topic><topic>Signs and symptoms</topic><topic>Substance use</topic><topic>Traumatic brain injury</topic><topic>Treatment Outcome</topic><topic>Veterans - psychology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cherian, Kirsten N.</creatorcontrib><creatorcontrib>Keynan, Jackob N.</creatorcontrib><creatorcontrib>Anker, Lauren</creatorcontrib><creatorcontrib>Faerman, Afik</creatorcontrib><creatorcontrib>Brown, Randi E.</creatorcontrib><creatorcontrib>Shamma, Ahmed</creatorcontrib><creatorcontrib>Keynan, Or</creatorcontrib><creatorcontrib>Coetzee, John P.</creatorcontrib><creatorcontrib>Batail, Jean-Marie</creatorcontrib><creatorcontrib>Phillips, Angela</creatorcontrib><creatorcontrib>Bassano, Nicholas J.</creatorcontrib><creatorcontrib>Sahlem, Gregory L.</creatorcontrib><creatorcontrib>Inzunza, Jose</creatorcontrib><creatorcontrib>Millar, Trevor</creatorcontrib><creatorcontrib>Dickinson, Jonathan</creatorcontrib><creatorcontrib>Rolle, C. E.</creatorcontrib><creatorcontrib>Keller, Jennifer</creatorcontrib><creatorcontrib>Adamson, Maheen</creatorcontrib><creatorcontrib>Kratter, Ian H.</creatorcontrib><creatorcontrib>Williams, Nolan R.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cherian, Kirsten N.</au><au>Keynan, Jackob N.</au><au>Anker, Lauren</au><au>Faerman, Afik</au><au>Brown, Randi E.</au><au>Shamma, Ahmed</au><au>Keynan, Or</au><au>Coetzee, John P.</au><au>Batail, Jean-Marie</au><au>Phillips, Angela</au><au>Bassano, Nicholas J.</au><au>Sahlem, Gregory L.</au><au>Inzunza, Jose</au><au>Millar, Trevor</au><au>Dickinson, Jonathan</au><au>Rolle, C. E.</au><au>Keller, Jennifer</au><au>Adamson, Maheen</au><au>Kratter, Ian H.</au><au>Williams, Nolan R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Magnesium–ibogaine therapy in veterans with traumatic brain injuries</atitle><jtitle>Nature medicine</jtitle><stitle>Nat Med</stitle><addtitle>Nat Med</addtitle><date>2024-02-01</date><risdate>2024</risdate><volume>30</volume><issue>2</issue><spage>373</spage><epage>381</epage><pages>373-381</pages><issn>1078-8956</issn><eissn>1546-170X</eissn><abstract>Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression and anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complications, leading some to seek underexplored treatment alternatives such as the oneirogen ibogaine, a plant-derived compound known to interact with multiple neurotransmitter systems that has been studied primarily as a treatment for substance use disorders. Ibogaine has been associated with instances of fatal cardiac arrhythmia, but coadministration of magnesium may mitigate this concern. In the present study, we report a prospective observational study of the Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS protocol (MISTIC), provided together with complementary treatment modalities, in 30 male SOVs with predominantly mild TBI. We assessed changes in the World Health Organization Disability Assessment Schedule from baseline to immediately (primary outcome) and 1 month (secondary outcome) after treatment. Additional secondary outcomes included changes in PTSD (Clinician-Administered PTSD Scale for DSM-5), depression (Montgomery–Åsberg Depression Rating Scale) and anxiety (Hamilton Anxiety Rating Scale). MISTIC resulted in significant improvements in functioning both immediately (
P
corrected
< 0.001, Cohen’s
d
= 0.74) and 1 month (
P
corrected
< 0.001,
d
= 2.20) after treatment and in PTSD (
P
corrected
< 0.001,
d
= 2.54), depression (
P
corrected
< 0.001,
d
= 2.80) and anxiety (
P
corrected
< 0.001,
d
= 2.13) at 1 month after treatment. There were no unexpected or serious adverse events. Controlled clinical trials to assess safety and efficacy are needed to validate these initial open-label findings. ClinicalTrials.gov registration:
NCT04313712
.
Military veterans with traumatic brain injuries who received treatment with the psychoactive compound ibogaine and magnesium experienced improvements in disability, psychiatric symptoms and cognition.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>38182784</pmid><doi>10.1038/s41591-023-02705-w</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9203-0730</orcidid><orcidid>https://orcid.org/0000-0001-9122-4525</orcidid><orcidid>https://orcid.org/0000-0001-8376-3406</orcidid><orcidid>https://orcid.org/0000-0002-6153-217X</orcidid><orcidid>https://orcid.org/0000-0003-4368-3203</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-8956 |
| ispartof | Nature medicine, 2024-02, Vol.30 (2), p.373-381 |
| issn | 1078-8956 1546-170X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10878970 |
| source | MEDLINE; Nature; SpringerLink Journals - AutoHoldings |
| subjects | 631/477 692/308/409 Anxiety Arrhythmia Biomedical and Life Sciences Biomedicine Brain Brain Injuries, Traumatic - drug therapy Cancer Research Clinical trials Cognition Complications Head injuries Humans Ibogaine Infectious Diseases Injuries Magnesium Magnesium - therapeutic use Mental depression Mental disorders Metabolic Diseases Military personnel Military psychology Molecular Medicine Neurosciences Observational studies Plants Post traumatic stress disorder Psychological stress Signs and symptoms Substance use Traumatic brain injury Treatment Outcome Veterans - psychology |
| title | Magnesium–ibogaine therapy in veterans with traumatic brain injuries |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T01%3A00%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Magnesium%E2%80%93ibogaine%20therapy%20in%20veterans%20with%20traumatic%20brain%20injuries&rft.jtitle=Nature%20medicine&rft.au=Cherian,%20Kirsten%20N.&rft.date=2024-02-01&rft.volume=30&rft.issue=2&rft.spage=373&rft.epage=381&rft.pages=373-381&rft.issn=1078-8956&rft.eissn=1546-170X&rft_id=info:doi/10.1038/s41591-023-02705-w&rft_dat=%3Cproquest_pubme%3E2918195637%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2928721635&rft_id=info:pmid/38182784&rfr_iscdi=true |